Ashwin Rammohan, 1 Mettu S. Reddy, 1 Mohammed Farouk, 1 Joy Vargese, 1 and Mohamed Rela 1, 2 T reatment options for hepatocellular carcinoma (HCC) recurrence following liver transplantation (LT) are extremely limited. (1) HCCs are a heterogenous group of tumors driven by inflammation and hence the rationale to evaluate immunotherapy in these patients. The immune checkpoint protein, programmed death receptor 1 (PD-1), is an inhibitory molecule expressed on the surface of multiple tissue types and keeps T cells from attacking tumor cells. (2) We report on a case of metastatic HCC following LT that responded dramatically to pembrolizumab, a PD-1 inhibitor, after failure of therapy with sorafenib.
Case Report
A 57-year-old gentleman presented to our unit in 2011 as a known case of hepatitis B chronic liver disease for 25 years with multifocal HCC detected initially in 2008. He had previously undergone multiple cycles of locoregional treatment (transarterial chemoembolization nine times and radiofrequency ablation five times) elsewhere.
On presentation to our unit, his liver function was unremarkable, and alpha fetoprotein level was 4.67 ng/ mL. Imaging revealed three lesions in the liver, with the largest measuring 4.5 cm, all showing signs of previous locoregional therapy. Chest computed tomography (CT) and bone scans were normal. He underwent living donor liver transplantation (LDLT) in January 2012 with a right lobe graft donated by his daughter. The operation and postoperative course were unremarkable. He was discharged on standard immunosuppression (tacrolimus, mycophenolate mofetil, and steroid). His explant liver histopathology revealed five well-differentiated tumors with no vascular invasion, showing varying degrees of necrosis (40%-80%), with the largest being 4.5 cm. He was well on follow-up with no evidence of recurrence for 3 years.
In May 2015, he presented with dyspnea and was noted to have multiple lung nodules. He underwent thoracoscopic biopsy, and these lesions were confirmed as metastatic HCC. His immunosuppression was modified to add mammalian target of rapamycin inhibitors (tacrolimus dose decreased to maintain a blood level of 2-3 ng/mL), and sorafenib was started. On follow-up, a year later, there was progression of disease with increase in size and number of the lung lesions; no lesions were noted elsewhere in the body. The patient remained clinically well with excellent graft function and performance status. In view of limited treatment options for the progressive lung metastases, he was started on pembrolizumab 200 mg once per 21 days along with sorafenib. He tolerated the medication without any adverse effects or graft rejection/dysfunction. Follow-up imaging after 3 months showed excellent response to the drug with complete radiological resolution (Fig. 1) . Ten months after starting therapy, he remains well on pembrolizumb and sorafenib with no radiological evidence of tumor.
Discussion
Posttransplant immunosuppression mitigates the antitumor protection offered by native immunity, allowing development and progression of these tumors. Response to treatment remains dismal, with a median survival of 5-15 months. (1) Pembrolizumab is a humanized monoclonal immunoglobulin against PD-1 that blocks the signaling of the PD-1 receptor, thus reversing immunosuppression induced by cancer cells and restoring the immune system, allowing it to regain its original ability to attack cancer cells.
(2) Despite our patient being immunosuppressed, pembrolizumab was effective in achieving a complete radiological remission of metastatic lesions. Interestingly, the native immune system boosted by the drug did not result in liver graft rejection, and our patient remains well. Although response has been noted in HCC, there are no known reports on a background of immunosuppression. (3, 4) Interesting questions arise on the drug's selective immune-mediated destruction of tumor cells while maintaining the immunosuppressive agents' immunomodulatory effects on the liver graft.
Conclusion
We report on a successful case of pembrolizumab therapy in metastatic HCC after LT on a background of posttransplant immunosuppression. PD-1 blockade may be a new option of treatment for advanced HCC; further studies will support/refute our findings.
